Detalhe da pesquisa
1.
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Ann Oncol
; 34(1): 48-60, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36182023
2.
Epigenetic modifiers as new immunomodulatory therapies in solid tumours.
Ann Oncol
; 29(4): 812-824, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29432557
3.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Ann Oncol
; 29(5): 1304-1311, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29788155
4.
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Ann Oncol
; 28(2): 254-269, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28426098
5.
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.
Ann Oncol
; 28(7): 1590-1596, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28449049
6.
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
Ann Oncol
; 27(11): 2004-2016, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27502726
7.
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Ann Oncol
; 27(2): 214-24, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26578728
8.
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
Ann Oncol
; 27(2): 344-52, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26598538
9.
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.
Ann Oncol
; 30(8): 1401-1403, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31114851
10.
Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups.
Ann Oncol
; 29(4): 798-799, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29528461
11.
Phase I-II trial designs: how early should efficacy guide the dose recommendation process?
Ann Oncol
; 29(3): 540-541, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29415188
12.
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Br J Cancer
; 103(3): 332-9, 2010 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20628389
13.
Phase I trials in oncology: a new era has started.
Ann Oncol
; 26(1): 7-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25361990
14.
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
Br J Cancer
; 100(9): 1373-8, 2009 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-19401696
15.
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
Ann Oncol
; 24(9): 2201-4, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23986546
16.
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.
Eur J Cancer
; 95: 68-74, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29635146
17.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Eur J Cancer
; 54: 139-148, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26765102
18.
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
Lung Cancer
; 85(1): 74-80, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24746176
19.
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Oncogene
; 32(47): 5377-87, 2013 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23934192
20.
[Dose finding methods for targeted agents: new perspectives]. / Méthodes pour la recherche de dose de traitements ciblés : nouvelles pistes.
Bull Cancer
; 97(12): 1485-95, 2010 Dec.
Artigo
em Francês
| MEDLINE | ID: mdl-21220226